Global Business Innovation Programme in India - Antimicrobial Resistance

A GBIP has three stages:

Prepare for the market

Preparing for the market includes the cohort being briefed by sector and market experts on, for example, cultural aspects of conducting business in that country. Delegates receive help to find business partners and arrange meetings and are advised on best practice including the management and protection of their intellectual property.

Visiting the market

Visiting the market provides opportunities to attend pre-arranged meetings and activities in order to better understand and maximise the opportunities that the visit presents.

Exploiting the opportunity

Exploiting the opportunity is arguably the most important aspect of the programme. To maximise the opportunity, participating companies are given bespoke one-to-one support from an Innovate UK EDGE innovation and growth specialist to help develop and implement an action plan.

The Global Business Innovation Programme operates on a competitive basis and businesses selected are required to participate in all three stages (some or all of which may be online).

To apply you must:

• Be a UK-based innovation- led company with ambitions to grow and internationalise
• Be a company with fewer than 500 employees
• Be able to attend and complete all activities

India has recognised the importance of AMR, and the Indian Ministry of Health and Family Welfare has established three technical bodies: The Intersectoral Coordination Committee, Technical Advisory Group, and Core Working Group to develop a National Action Plan on AMR (NAP-AMR).

The NAP-AMR, largely modelled on the World Health Organisation’s (WHO) – global action plan on AMR, highlights the crucial need to prevent the development of new resistant organisms, limiting their transmission and further spread as an international issue.

The 5-year NAP-AMR (2017–2021) was intended as a pivotal blueprint for states to develop their own state action plans to tackle AMR. However, only three states out of 28 (0.84% of the country) have established state action plans, namely Kerala, Madhya Pradesh, and Delhi.

The strategic implementation began in early 2017, determining six strategic fields of activity and objectives that recognise cooperation between different areas, ensuring each one’s integrity — a One Health approach. Consequently, there is a significant AMR Ecosystem within India.

The GBIP will include a visit to both Bangalore, the capital of Karnataka and Hyderabad, the capital of Telangana.

These two cities stand out as technology hubs with advanced healthcare infrastructure and a thriving innovation ecosystem. C Camp Bangalore is such an example which operates an initiative supported by the Department of Biotechnology, Govt of India, wherein a team of UK and Indian researchers are working together to tackle the rising prevalence of Antimicrobial Resistance (AMR) in the environment.

Leveraging the expertise, resources and collaborative networks in these two cities may significantly impact AMR mitigation efforts nationwide and globally.

Innovate UK will fund and organise flights, accommodation, and any conference fees for successful applicants. Innovate UK will also pay for any reasonable adjustments throughout the initiative.

Only one representative from each company will be funded. On acceptance, a commitment fee of £500 (excluding VAT) will be obtained from each delegate, which will be refunded on completion of the full activities and agreed action plan.

Non-completion after formal acceptance may result in forfeiting some or all of the commitment fees.

Application deadline: 15th April 2024
Pre-visit briefing: 8th – 9th May 2024
Innovation visit: 22nd – 29th June 2024
Post-Exploitation workshop: 20th August 2024